Unlocking Hope for Cancer Patients Using PDT
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL
8
•
•
.
Immune checkpoint inhibitors (ICI), a type of immunotherapy, is standard of care in treatment of several cancers
• Despite widespread use of ICIs, the patient response rate can be as low as 12.5%¹
Independent in vivo studies showed combined INV043 and anti-PD-1 therapies achieved 80% tumour elimination
HUDSON INSTITUTE:. ~65% REDUCTION IN TUMOUR VOLUME
(TRIPLE NEGATIVE BREAST CANCER, INTRATUMORAL)²
4T1 breast tumours treated using a restricted INV043 PDT protocol
(intratumoural) and / or anti PD-1 antibody (intratumoral)
Monotherapies restricted tumour growth vs untreated controls
Combination therapy regressed and stabilized tumours and
achieved a ~65% reduction in tumour size at endpoint
(n=4/group)
Tumour volume (mm²)
150-
100
50-
PDT #1
10
PDT #2
20
T
30
40
Days post tumour-inoculation
INV043 control
IgG2a control
+ anti-PD-1 alone
⚫ PDT (restricted)
combination
Combi therapy:
-65% increase in
effectiveness vs.
ICI alone
PETER MAC: -80% RESPONSE RATE
(ANAL SCC CANCER, TOPICAL)³
Anal Squamous Cell Carcinoma (ASCC) tumours treated using a
restricted INV043 PDT protocol (topical) and / or anti PD-1 antibody
Monotherapies restricted tumour growth vs untreated controls, with
standalone INV043 showing lower tumour volume vs ICI alone
Combination therapy resulted in 80% tumour-free subjective at
endpoint (n=8-10/group)
%Tumor free
100
80-
60-
40
20-
0
10
20
20
***
INV043+PD1 vs Vehicle = p=0.001
** INV043+PD1 vs PD1 p=0.0037
*
INV043 vs Vehicle p=0.0397
30
40
Days
1 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2762389
2 https://announcements.asx.com.au/asxpdf/20220530/pdf/459ffkjbvdpjrg.pdf
3 Per ASX announcement 4 March 2024
-
7/10, no measurable tumour.
8th mouse histology, no
evidence of tumour cells
50
INVO43 PD-1
60
60
INVO43 Isotype Control
Vehicle PD-1
Vehicle Isotype Control
**
*******View entire presentation